ArticleJournal of medical physics
Independent Three-dimensional Dose Calculation from Log Files for Breast VMAT: A Measurement-free Quality Assurance Approach.
Article in Journal of medical physics. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: The purpose of this study was to evaluate and validate a measurement-free patient-specific quality assurance (PSQA) approach for volumetric modulated arc therapy (VMAT) breast cancer treatments based on independent three-dimensional (3D) dose calculation from Digital Imaging and Communications in Medicine (DICOM) plans and linear accelerator log files. Materials and Methods: Seventy clinical breast VMAT plans (36 left-sided and 34 right-sided) were retrospectively analyzed. Independent 3D dose calculations were performed using RadCalc v7.3 based on the DICOM treatment plan (independent dose calculation [IDC] RTPlan) and on delivery log files acquired during the first treatment fraction (IDC LOGs). Results were compared with portal dosimetry (two-dimensional [2D]) and fluence-based analysis. Gamma passing rates (GPRs) were evaluated using 3%/2 mm and 2%/2 mm criteria under action (90%) and tolerance (95%) limits. Receiver operating characteristic (ROC) analysis was performed to evaluate the discriminatory capability. Sensitivity to delivery errors was investigated by introducing controlled multileaf collimator (MLC) shifts (0.5-2.0 mm) and collimator rotation errors (1°-3°). Results: All PSQA methods met the TG-218 action limit (GPR ≥ 90%) at 3%/2 mm. Under the stricter 2%/2 mm criterion, statistically significant differences among quality assurance methods were observed ( Conclusions: Independent 3D dose calculation is a reliable PSQA approach for breast VMAT, showing higher sensitivity than conventional 2D methods.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.